Skip to content

Usability of Diabetes Dashboard Embedded Within a Patient Web Portal

Usability of Diabetes Dashboard Embedded Within a Patient Web Portal: A Prospective Longitudinal Study

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03786718
Enrollment
69
Registered
2018-12-26
Start date
2018-12-27
Completion date
2019-05-13
Last updated
2023-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes Mellitus, Type 2

Keywords

Diabetes, Patient Web Portals, Usability, Health Information Technology

Brief summary

The purpose of this study is to conduct a prospective, longitudinal study to evaluate the usability of a patient-facing diabetes dashboard delivered via an established patient web portal.

Detailed description

Up to 70 adult patients with type 2 diabetes mellitus will be enrolled and given access to a diabetes dashboard within an existing patient web portal. Patients will be invited by mail (or email) to be screened for enrollment in the study. Patients may also respond at a study flyer and contact the study team to be screened for enrollment. Eligible and interested patients will be emailed a link to a secure study website where they will complete a web consent form. After enrollment, participants will complete a baseline web-based questionnaire. After completing the enrollment questionnaire, they will be provided access to the diabetes dashboard within the patient web portal for one month. After one month, participants will receive an additional follow-up (final) questionnaire to assess outcomes.

Interventions

OTHERPatient-facing Diabetes Dashboard

The Patient-facing Diabetes Dashboard is embedded within a patient web portal and includes graphics to visualize and summarize patients' health data, incorporates motivational strategies (e.g., social comparisons and gamification), provides literacy level appropriate educational resources, and contains secure-messaging capability.

Sponsors

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
CollaboratorNIH
Vanderbilt University Medical Center
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
21 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Type 2 Diabetes Mellitus * Currently being treated with at least one antihyperglycemic medication * Able to speak and read in English * Have reliable access to a computer with internet access * Existing My Health at Vanderbilt (i.e., patient portal) account

Exclusion criteria

* Living in long term care facilities * Known cognitive deficits * Severe visual or hearing impairment * Unintelligible speech (e.g., dysarthria) * Currently participating in another diabetes-related research study

Design outcomes

Primary

MeasureTime frameDescription
Usabilityone month follow-up (T1)The System Usability Scale (SUS) will be administered to all study participants at one month follow-up (T1). The SUS is a validated measure of usability. The ten items are scored on a five-point Likert scale. The item scores are summed and then converted to a score ranging from 0 (worst) to 100 (best). A score of above 68 indicative of above average usability.
User Experience - Quantitativeone month follow-up (T1)User experience will be assessed by study-specific survey items administered to all study participants at the end of the study period (T1). The survey items will inquire about participants' perspectives on particular features of the Patient-facing Diabetes Dashboard. Participants were asked to indicate which features, if any: (1) they found useful for managing their diabetes and which features, (2) improved their understanding of their diabetes health data, and (3) should be removed. In addition, participants indicated whether they intended to use the dashboard going forward if it remained available.
User Experience - Qualitativeone month follow-up (T1)At the end of the study period (T1), a subset of study participants will be invited to complete a semi-structured interview to provide a deeper understanding of their experience using the dashboard.

Secondary

MeasureTime frameDescription
Change in Diabetes Self-Efficacyenrollment (T0) and one month follow-up (T1)The Perceived Diabetes Self-Management Scale (PDSMS) is a valid measure of diabetes self-efficacy. The PDSMS will be administered to all study participants at enrollment (T0) and one month follow-up (T1). Eight items are scored on a five-point Likert scale. The total PDSMS score can range from 8 to 40, with higher scores indicating more confidence in self-managing one's diabetes.
Change in Diabetes Distressenrollment (T0) and one month follow-up (T1)The Problem Areas in Diabetes Scale (PAID-5) is a valid measure of diabetes distress. The PAID-5 will be administered to all study participants at enrollment (T0) and one month follow-up (T1). Total scores on the PAID-5 can range from 0 to 20, with higher scores suggesting greater diabetes-related emotional distress.
Change in Knowledge of Diabetes Measuresenrollment (T0) and one month follow-up (T1)Unique study specific items to assess participants' knowledge of measures of diabetes health status (e.g., Hemoglobin A1C) will be administered to all study participants at enrollment (T0) and one month follow-up (T1).
System Usage Dataone month follow-up (T1)This is a composite outcome measure of participants' self-reported total number of diabetes dashboard visits, total duration of dashboard use, use of embedded educational links, utilization of embedded functionality to secure message healthcare team member(s), and use of an embedded link to American Diabetes Association Online Community and will be queried at the end of the study period (T1).
Change in Attitudesenrollment (T0) and one month follow-up (T1)Unique study specific survey items to assess participants' attitudes toward receiving social and goal-based comparison information regarding their diabetes health status will be administered to all study participants at enrollment (T0) and one month follow-up (T1).
Change in Patient Activationenrollment (T0) and one month follow-up (T1)The Patient Activation Measure® (PAM-13) scale will be administered to all study participants at enrollment (T0) and one month follow-up (T1). The 13-item PAM® survey is a validated measure of patient activation (i.e., the knowledge, skills and confidence a person has in managing their own health and health care) and consists of 13 items. Each item uses a 4-point Likert-type scale of response options ranging from strongly disagree to strongly agree to elicit endorsement of a particular statement. PAM® survey item responses result in total raw scores ranging from 13 to 52, which we converted to the linear interval scale of patient activation scores, ranging from 0 (lowest activation) to 100 (highest activation).
Change in Diabetes Understandingenrollment (T0) and one month follow-up (T1)The Diabetes Care Profile (DCP) is a self-administered questionnaire that assesses the social and psychological factors related to diabetes and its treatment. The instrument includes sixteen scales. The Understanding Scale of the DCP contains 13 items that assesses respondents' perceived understanding of elements of diabetes self-care (e.g., diet for blood sugar control). We administered 9 of the 13 items to study participants, excluding items that referenced elements of self-management that are not covered in My Diabetes Care (e.g., pregnancy and diabetes). Respondents rate their understanding on a five-point Likert scale. The scale scores range from 1 to 5 and represents the average item score for the scale (∑ Q1-9/ Count of non-missing items). High scores indicate higher perceived understanding.
Change in Diabetes Knowledgeenrollment (T0) and one month follow-up (T1)The Short Diabetes Knowledge Instrument (SDKI) was used to measure diabetes knowledge including diabetes diet, symptoms of hypoglycemia, foot care and importance of physical activity. The SDKI is a 13-item scale with scores ranging from 0 to 13 representing number of items answered correctly. The Short Diabetes Knowledge Instrument (SDKI) will be administered to all study patients at enrollment (T0) and one month follow-up (T1).
Change in Diabetes Self-Careenrollment (T0) and one month follow-up (T1)Diabetes self-care will be measured using the Summary of Diabetes Self-Care Activities (SDSCA), an 11-item questionnaire of diabetes self-management that assess the following six aspects of the diabetes regimen: general diet (2 items), specific diet (2 items), exercise (2 items), blood-glucose testing (2 items), foot care (2 items), and smoking (1 items). Item responses use the metric days per week except for a single item about smoking status which is yes or no. Each of the five aspects (excluding smoking) is assigned a mean score based on number of days per week. The Summary of Diabetes Self-Care Activities (SDSCA) will be administered to all study patients at enrollment (T0) and one month follow-up (T1).

Countries

United States

Participant flow

Pre-assignment details

Of the 69 enrolled participants, 67 completed the baseline questionnaire and were with given access to the intervention. Two participants never completed the baseline questionnaire despite reminders and therefore did not receive access to the intervention and were withdrawn.

Participants by arm

ArmCount
Intervention
Patients have access to a patient web portal with the Patient-facing Diabetes Dashboard activated. Patient-facing Diabetes Dashboard: The Patient-facing Diabetes Dashboard (also known as My Diabetes Care) is embedded within a patient web portal and includes graphics to visualize and summarize patients' health data, incorporates motivational strategies (e.g., social comparisons), provides literacy level appropriate educational resources, and contains secure-messaging capability.
60
Total60

Withdrawals & dropouts

PeriodReasonFG000
Overall Studydiagnosis changed from type 2 to type 11
Overall StudyDid not use the intervention2
Overall StudyLost to Follow-up3
Overall StudyWithdrawal by Subject1

Baseline characteristics

CharacteristicIntervention
Age, Categorical
<=18 years
0 Participants
Age, Categorical
>=65 years
20 Participants
Age, Categorical
Between 18 and 65 years
40 Participants
Age, Continuous57.5 years
STANDARD_DEVIATION 13
Comorbidities
Hyperlipidemia
47 participants
Comorbidities
Hypertension
51 participants
Computer and Smartphone Usage
Desktop
50 participants
Computer and Smartphone Usage
Smartphone
52 participants
Computer and Smartphone Usage
Tablet
40 participants
Education
College degree
19 Participants
Education
Graduate or professional degree
12 Participants
Education
High school/GED
5 Participants
Education
Some college/technical school
24 Participants
eHealth Literacy31.5 units on a scale
STANDARD_DEVIATION 5.2
Ethnicity (NIH/OMB)
Hispanic or Latino
2 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
58 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants
Health Literacy
Adequate
31 Participants
Health Literacy
Limited
29 Participants
Hemoglobin A1c7.5 %
STANDARD_DEVIATION 1.6
Insulin Use
No
36 Participants
Insulin Use
Yes
24 Participants
Patient Portal Usage
Monthly
29 Participants
Patient Portal Usage
Other
5 Participants
Patient Portal Usage
Weekly
26 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
Race (NIH/OMB)
Asian
1 Participants
Race (NIH/OMB)
Black or African American
13 Participants
Race (NIH/OMB)
More than one race
3 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
Race (NIH/OMB)
Unknown or Not Reported
2 Participants
Race (NIH/OMB)
White
41 Participants
Region of Enrollment
United States
60 participants
Sex: Female, Male
Female
33 Participants
Sex: Female, Male
Male
27 Participants
Time with diagnosis of diabetes13.1 years
STANDARD_DEVIATION 10

Adverse events

Event typeEG000
affected / at risk
deaths
Total, all-cause mortality
0 / 67
other
Total, other adverse events
0 / 67
serious
Total, serious adverse events
0 / 67

Outcome results

Primary

Usability

The System Usability Scale (SUS) will be administered to all study participants at one month follow-up (T1). The SUS is a validated measure of usability. The ten items are scored on a five-point Likert scale. The item scores are summed and then converted to a score ranging from 0 (worst) to 100 (best). A score of above 68 indicative of above average usability.

Time frame: one month follow-up (T1)

Population: All 60 participants that completed the study (i.e., used the intervention and complete pre- and post-questionnaires.

ArmMeasureValue (MEDIAN)
InterventionUsability78.8 score on a scale
Comparison: Due to nonnormality, we used nonparametric tests to analyze the data. This analysis is a one sample median test of participants' median SUS score compared to the threshold score of 68 indicative of 'above average' usability.p-value: <0.001One sample median test
Primary

User Experience - Qualitative

At the end of the study period (T1), a subset of study participants will be invited to complete a semi-structured interview to provide a deeper understanding of their experience using the dashboard.

Time frame: one month follow-up (T1)

Population: participants that participated in a semi-structured interview

ArmMeasureValue (NUMBER)
InterventionUser Experience - Qualitative5 areas for improvement identified
Primary

User Experience - Quantitative

User experience will be assessed by study-specific survey items administered to all study participants at the end of the study period (T1). The survey items will inquire about participants' perspectives on particular features of the Patient-facing Diabetes Dashboard. Participants were asked to indicate which features, if any: (1) they found useful for managing their diabetes and which features, (2) improved their understanding of their diabetes health data, and (3) should be removed. In addition, participants indicated whether they intended to use the dashboard going forward if it remained available.

Time frame: one month follow-up (T1)

ArmMeasureGroupValue (NUMBER)
InterventionUser Experience - QuantitativeStar Status Indicator - useful19 participants
InterventionUser Experience - QuantitativeHover Over Info Icons - useful26 participants
InterventionUser Experience - QuantitativePatients Like Me Data - useful40 participants
InterventionUser Experience - QuantitativeHover Over Info Icons - removed0 participants
InterventionUser Experience - QuantitativeGoal, Caution, and Warning Ranges - removed2 participants
InterventionUser Experience - QuantitativePatients Like Me Data - removed4 participants
InterventionUser Experience - QuantitativeLiteracy Sensitive Education Links - removed0 participants
InterventionUser Experience - QuantitativeDiabetes Online Community - removed1 participants
InterventionUser Experience - QuantitativeIntend to use going forward60 participants
InterventionUser Experience - QuantitativeGoal, Caution, and Warning Ranges - understanding39 participants
InterventionUser Experience - QuantitativeGoal, Caution, and Warning Ranges - useful46 participants
InterventionUser Experience - QuantitativeLiteracy Sensitive Education Links - useful40 participants
InterventionUser Experience - QuantitativeDiabetes Online Community - useful22 participants
InterventionUser Experience - QuantitativeStar Status Indicator - understanding18 participants
InterventionUser Experience - QuantitativeHover Over Info Icons - understanding31 participants
InterventionUser Experience - QuantitativeLiteracy Sensitive Education Links - understanding39 participants
InterventionUser Experience - QuantitativeDiabetes Online Community - understanding15 participants
InterventionUser Experience - QuantitativeStar Status Indicator - removed4 participants
Secondary

Change in Attitudes

Unique study specific survey items to assess participants' attitudes toward receiving social and goal-based comparison information regarding their diabetes health status will be administered to all study participants at enrollment (T0) and one month follow-up (T1).

Time frame: enrollment (T0) and one month follow-up (T1)

ArmMeasureGroupValue (NUMBER)
InterventionChange in AttitudesInterested in social comparison info at T051 participants
InterventionChange in AttitudesInterested in social comparison info at T146 participants
InterventionChange in AttitudesInterested goal-based comparison info at T058 participants
InterventionChange in AttitudesInterested goal-based comparison info at T159 participants
InterventionChange in AttitudesAgree social comparison info is useful at T049 participants
InterventionChange in AttitudesAgree social comparison info is useful at T146 participants
InterventionChange in AttitudesAgree goal-based comparison info is useful at T059 participants
InterventionChange in AttitudesAgree goal-based comparison info is useful at T157 participants
Comparison: Analysis of pre-post change in interest in information about how my diabetes health data compares to other patients like me (i.e., social comparison information)p-value: 0.23McNemar
Comparison: Analysis of pre-post change in interest in information about how their diabetes health data compares to the goal range (i.e., goal-based comparison information)p-value: 1McNemar
Comparison: Analysis of pre-post change in agreement with statement: 'Information about how my diabetes health data compares to other patients like me \[social comparison information\] is useful.'p-value: 0.51McNemar
Comparison: Analysis of pre-post change in agreement with statement: 'Information about how my diabetes health data compares to the goals range \[goal-based comparison information\] is useful.p-value: 0.63McNemar
Secondary

Change in Diabetes Distress

The Problem Areas in Diabetes Scale (PAID-5) is a valid measure of diabetes distress. The PAID-5 will be administered to all study participants at enrollment (T0) and one month follow-up (T1). Total scores on the PAID-5 can range from 0 to 20, with higher scores suggesting greater diabetes-related emotional distress.

Time frame: enrollment (T0) and one month follow-up (T1)

Population: Missing data for one participant.

ArmMeasureGroupValue (MEDIAN)
InterventionChange in Diabetes Distressenrollment (T0)5.0 score on a scale
InterventionChange in Diabetes Distressone month follow-up (T1)5.0 score on a scale
p-value: 0.86Wilcoxon Signed Rank Sum test
Secondary

Change in Diabetes Knowledge

The Short Diabetes Knowledge Instrument (SDKI) was used to measure diabetes knowledge including diabetes diet, symptoms of hypoglycemia, foot care and importance of physical activity. The SDKI is a 13-item scale with scores ranging from 0 to 13 representing number of items answered correctly. The Short Diabetes Knowledge Instrument (SDKI) will be administered to all study patients at enrollment (T0) and one month follow-up (T1).

Time frame: enrollment (T0) and one month follow-up (T1)

Population: Missing data for one participant

ArmMeasureGroupValue (MEDIAN)
InterventionChange in Diabetes Knowledgeenrollment (T0)11.0 score on a scale
InterventionChange in Diabetes Knowledgeone month follow-up (T1)11.0 score on a scale
p-value: 0.77Wilcoxon Signed Rank Sum test
Secondary

Change in Diabetes Self-Care

Diabetes self-care will be measured using the Summary of Diabetes Self-Care Activities (SDSCA), an 11-item questionnaire of diabetes self-management that assess the following six aspects of the diabetes regimen: general diet (2 items), specific diet (2 items), exercise (2 items), blood-glucose testing (2 items), foot care (2 items), and smoking (1 items). Item responses use the metric days per week except for a single item about smoking status which is yes or no. Each of the five aspects (excluding smoking) is assigned a mean score based on number of days per week. The Summary of Diabetes Self-Care Activities (SDSCA) will be administered to all study patients at enrollment (T0) and one month follow-up (T1).

Time frame: enrollment (T0) and one month follow-up (T1)

Population: The overall number of participants analyzed for two blood-glucose testing items was 50, because 10 participants that do not test their blood sugar were excluded from those two items. Overall number of participants analyzed was 60 for the the other five aspects/sub-scales.

ArmMeasureGroupValue (MEDIAN)
InterventionChange in Diabetes Self-Caregeneral diet at enrollment (T0)4.0 days per week
InterventionChange in Diabetes Self-Caregeneral diet at one month follow-up (T1)4.0 days per week
InterventionChange in Diabetes Self-Carespecific diet at one month follow-up (T1)4.0 days per week
InterventionChange in Diabetes Self-Careexercise at enrollment (T0)2.5 days per week
InterventionChange in Diabetes Self-Careblood-glucose testing at one month follow-up (T1)6.0 days per week
InterventionChange in Diabetes Self-Carefoot care at enrollment (T0)3.5 days per week
InterventionChange in Diabetes Self-Carefoot care at one month follow-up (T1)3.0 days per week
InterventionChange in Diabetes Self-Carespecific diet at enrollment (T0)3.5 days per week
InterventionChange in Diabetes Self-Careexercise at one month follow-up (T1)2.3 days per week
InterventionChange in Diabetes Self-Careblood-glucose testing at enrollment (T0)5.3 days per week
Comparison: Analysis for pre-post change in General Diet sub-scale scorep-value: 0.02Wilcoxon Signed Rank Sum test
Comparison: Analysis for pre-post change in Specific Diet sub-scale scorep-value: 0.13Wilcoxon Signed Rank Sum test
Comparison: Analysis for pre-post change in Exercise sub-scale scorep-value: 0.35Wilcoxon Signed Rank Sum test
Comparison: Analysis for pre-post change in Blood-glucose Testing sub-scale scorep-value: 0.67Wilcoxon Signed Rank Sum test
Comparison: Analysis for pre-post change in Foot Care sub-scale scorep-value: 0.65Wilcoxon Signed Rank Sum test
Secondary

Change in Diabetes Self-Efficacy

The Perceived Diabetes Self-Management Scale (PDSMS) is a valid measure of diabetes self-efficacy. The PDSMS will be administered to all study participants at enrollment (T0) and one month follow-up (T1). Eight items are scored on a five-point Likert scale. The total PDSMS score can range from 8 to 40, with higher scores indicating more confidence in self-managing one's diabetes.

Time frame: enrollment (T0) and one month follow-up (T1)

Population: One participant had missing data.

ArmMeasureGroupValue (MEDIAN)
InterventionChange in Diabetes Self-Efficacyenrollment (T0)26.0 score on a scale
InterventionChange in Diabetes Self-Efficacyone month follow-up (T1)29.0 score on a scale
p-value: 0.001Wilcoxon Signed Rank Sum test
Secondary

Change in Diabetes Understanding

The Diabetes Care Profile (DCP) is a self-administered questionnaire that assesses the social and psychological factors related to diabetes and its treatment. The instrument includes sixteen scales. The Understanding Scale of the DCP contains 13 items that assesses respondents' perceived understanding of elements of diabetes self-care (e.g., diet for blood sugar control). We administered 9 of the 13 items to study participants, excluding items that referenced elements of self-management that are not covered in My Diabetes Care (e.g., pregnancy and diabetes). Respondents rate their understanding on a five-point Likert scale. The scale scores range from 1 to 5 and represents the average item score for the scale (∑ Q1-9/ Count of non-missing items). High scores indicate higher perceived understanding.

Time frame: enrollment (T0) and one month follow-up (T1)

Population: Missing data for one participant

ArmMeasureGroupValue (MEDIAN)
InterventionChange in Diabetes Understandingenrollment (T0)3.4 score on a scale
InterventionChange in Diabetes Understandingone month follow-up (T1)3.7 score on a scale
p-value: 0.15Wilcoxon Signed Rank Sum test
Secondary

Change in Knowledge of Diabetes Measures

Unique study specific items to assess participants' knowledge of measures of diabetes health status (e.g., Hemoglobin A1C) will be administered to all study participants at enrollment (T0) and one month follow-up (T1).

Time frame: enrollment (T0) and one month follow-up (T1)

Population: As noted in the outcome measure data table below, the number analyzed for some items is less than 60 due to missing data.

ArmMeasureGroupValue (NUMBER)
InterventionChange in Knowledge of Diabetes MeasuresIdentify definition of A1c at T040 participants
InterventionChange in Knowledge of Diabetes MeasuresIdentify definition of A1c at T145 participants
InterventionChange in Knowledge of Diabetes MeasuresIdentify goal range for A1c at T050 participants
InterventionChange in Knowledge of Diabetes MeasuresIdentify goal range for A1c at T150 participants
InterventionChange in Knowledge of Diabetes MeasuresIdentify definition of blood pressure at T043 participants
InterventionChange in Knowledge of Diabetes MeasuresIdentify definition of LDL cholesterol at T022 participants
InterventionChange in Knowledge of Diabetes MeasuresIdentify definition of LDL cholesterol at T125 participants
InterventionChange in Knowledge of Diabetes MeasuresIdentify goal range for LDL cholesterol at T015 participants
InterventionChange in Knowledge of Diabetes MeasuresIdentify goal range for LDL cholesterol at T131 participants
InterventionChange in Knowledge of Diabetes MeasuresIdentify definition of flu vaccine at T058 participants
InterventionChange in Knowledge of Diabetes MeasuresIdentify definition of flu vaccine at T159 participants
InterventionChange in Knowledge of Diabetes MeasuresIdentify frequency of flu vaccination at T058 participants
InterventionChange in Knowledge of Diabetes MeasuresIdentify frequency of flu vaccination at T159 participants
InterventionChange in Knowledge of Diabetes MeasuresIdentify definition of blood pressure at T146 participants
InterventionChange in Knowledge of Diabetes MeasuresIdentify goal range for blood pressure at T017 participants
InterventionChange in Knowledge of Diabetes MeasuresIdentify goal range for blood pressure at T128 participants
Comparison: Analysis for pre-post change in knowledge of definition of A1Cp-value: 0.3McNemar
Comparison: Analysis for pre-post change in knowledge of goal range for hemoglobin A1c.p-value: 1McNemar
Comparison: Analysis for pre-post change in knowledge of definition of systolic blood pressurep-value: 0.63McNemar
Comparison: Analysis of pre-post change in knowledge of goal range for systolic blood pressurep-value: 0.02McNemar
Comparison: Analysis of pre-post change in knowledge of definition of LDL cholesterolp-value: 0.55McNemar
Comparison: Analysis for pre-post change in knowledge of goal range for LDL cholesterolp-value: 0.0009McNemar
Comparison: Analysis of pre-post change in knowledge of definition of flu vaccinep-value: 1McNemar
Comparison: Analysis of pre-post change in knowledge of recommended frequency of flu vaccinationp-value: 1McNemar
Secondary

Change in Patient Activation

The Patient Activation Measure® (PAM-13) scale will be administered to all study participants at enrollment (T0) and one month follow-up (T1). The 13-item PAM® survey is a validated measure of patient activation (i.e., the knowledge, skills and confidence a person has in managing their own health and health care) and consists of 13 items. Each item uses a 4-point Likert-type scale of response options ranging from strongly disagree to strongly agree to elicit endorsement of a particular statement. PAM® survey item responses result in total raw scores ranging from 13 to 52, which we converted to the linear interval scale of patient activation scores, ranging from 0 (lowest activation) to 100 (highest activation).

Time frame: enrollment (T0) and one month follow-up (T1)

ArmMeasureGroupValue (MEDIAN)
InterventionChange in Patient Activationenrollment (T0)64.3 score on a scale
InterventionChange in Patient Activationone month follow-up (T1)67.8 score on a scale
p-value: 0.01Wilcoxon Signed Rank Sum test
Secondary

System Usage Data

This is a composite outcome measure of participants' self-reported total number of diabetes dashboard visits, total duration of dashboard use, use of embedded educational links, utilization of embedded functionality to secure message healthcare team member(s), and use of an embedded link to American Diabetes Association Online Community and will be queried at the end of the study period (T1).

Time frame: one month follow-up (T1)

ArmMeasureGroupValue (COUNT_OF_PARTICIPANTS)
InterventionSystem Usage DataTotal number of visits: 1-212 Participants
InterventionSystem Usage DataTotal number of visits: 3-427 Participants
InterventionSystem Usage DataTotal number of visits: 5-612 Participants
InterventionSystem Usage DataTotal number of visits: 7+9 Participants
InterventionSystem Usage DataTotal minutes spent: <5 minutes4 Participants
InterventionSystem Usage DataTotal minutes spent: 5-9 minutes7 Participants
InterventionSystem Usage DataTotal minutes spent: 10-14 minutes19 Participants
InterventionSystem Usage DataTotal minutes spent: 15+ minutes30 Participants
InterventionSystem Usage DataUsed literacy sensitive education links51 Participants
InterventionSystem Usage DataUsed secure messaging10 Participants
InterventionSystem Usage DataUsed diabetes online community16 Participants
InterventionSystem Usage DataUsed info icon with explanation of health measure49 Participants

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026